Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II trial of BI 187004 (VTP-34072) in patients with type 2 diabetes mellitus

Next Previous
Trial Profile

Phase II trial of BI 187004 (VTP-34072) in patients with type 2 diabetes mellitus

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Dec 2015

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BI 187004 CL (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Proof of concept; Therapeutic Use
  • Sponsors Boehringer Ingelheim

Most Recent Events

  • 17 Dec 2015 According to Vitae media release, company anticipated based on these earlier results, in this remaining monotherapy arm of the trial, BI187004 did not achieve the predefined primary efficacy endpoint criteria and hence, Boehringer Ingelheim has informed Vitae of its intention to terminate the program and its corresponding license agreement.
  • 17 Dec 2015 Results published in Vitae Pharmaceuticals media release.
  • 04 Aug 2015 Top-line efficacy results from the metformin arm have been reported, according to a Vitae Pharmaceuticals media release. Results from the ongoing, placebo-controlled monotherapy arm are expected to be reported later in 2015.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top